These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32702801)

  • 1. Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study.
    Wushouer H; Luo Z; Guan X; Shi L
    Int J Health Policy Manag; 2022 Feb; 11(2):218-223. PubMed ID: 32702801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study.
    Guan X; Wushouer H; Yang M; Han S; Shi L; Ross-Degnan D; Wagner AK
    BMJ Open; 2019 Nov; 9(11):e031658. PubMed ID: 31784440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
    Rong X; Yin J; Duan S; Sun Q; Babar ZU
    BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
    Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
    Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
    Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does price deregulation increase drug price in China? An interrupted time series analysis.
    Xiong Y; Xu J; Gao Y
    Int J Health Plann Manage; 2021 Sep; 36(5):1653-1665. PubMed ID: 34028086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short- and long-term impacts of the National Essential Medicines Policy on drug availability, price, and usage in a deprived rural county in southwestern China: an interrupted time series analysis across 8 years.
    Xiong X; Huo Z; Zhou S; Bai G; He S; Zhou Y; Jia J; Quan J; Luo L
    Front Public Health; 2024; 12():1355239. PubMed ID: 39267638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
    Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
    BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.
    Zhang L; Wang X; Yao H; Ding B; Gao X; Li X
    Int J Equity Health; 2024 Jun; 23(1):116. PubMed ID: 38840134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
    Zhao B; Wu J
    Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.
    Yi H; Shi F; Wang Z; Kuai L; Xu D; Xie Y; Xing H
    BMJ Open; 2023 Oct; 13(10):e064811. PubMed ID: 37852769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.
    Ding Y; Zheng C; Wei X; Zhang Q; Sun Q
    BMC Public Health; 2022 Dec; 22(1):2363. PubMed ID: 36527037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
    Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
    Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
    Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
    Zhu D; Shi X; Nicholas S; Bai Q; He P
    BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impacts of the national centralized drug procurement policy on the use of policy-related antibiotic agents: the case of Shaanxi province, China.
    Yang C; Ye D; Yan K; Xiang C; Liu S; Gu J; Liu Y; Fang Y
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):675-684. PubMed ID: 37013799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of China's zero mark-up drug policy on drug cost of NCDs' outpatients: an interrupted time series analysis.
    Du J; Xie J; Qian Y; Wu M; Huang W; Yin J; Peng X; Deng D
    BMC Health Serv Res; 2021 Apr; 21(1):404. PubMed ID: 33926444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
    Wang J; Li P; Wen J
    BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
    Wang N; Yang Y; Xu L; Mao Z; Cui D
    BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An empirical study of the impact of generic drug competition on drug market prices in China.
    Yina C; Pengcheng L; Haomiao N; Yang C
    Front Public Health; 2023; 11():1146531. PubMed ID: 37304112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.